MI/26/46 Postdoctoral Scientist

Key Details

Job ID:
MI/26/46
Role:
Postdoctoral Scientist
Salary:
£39,253 – £47,543 per annum (dependent upon experience)
Closing date:
4th October 2026

About the role

We are seeking a Postdoctoral Scientist to join the Stem Cell Biology group led by Prof Georges Lacaud. The group aims to improve outcomes for patients with leukaemia and other cancers by identifying therapeutic opportunities and developing robust approaches for the in vitro generation of blood and immune cells for cellular immunotherapy and transplantation. Autologous CAR-T cells have transformed the treatment of some leukaemias, but current therapies remain expensive, complex to manufacture and tailored to individual patients. Differentiation of human pluripotent stem cells (PSCs) offers a promising route to scalable, off-the-shelf allogeneic cell therapies; however, progress is limited by our incomplete understanding of early human T-cell development. The central question of this project is how human haemogenic endothelium gives rise to pro-T-cell progenitors and how these progenitors acquire the capacity to generate αβ and γδ T cells. The programme will define the mechanisms controlling the emergence and developmental potential of pro-T-cell progenitors and use this knowledge to improve their generation in vitro.

 

You will establish and use experimental models of human blood and immune development to investigate how pro-T-cell progenitors emerge and how intrinsic regulatory programmes and environmental signals shape their developmental potential. The project will integrate cellular, molecular and functional studies with high-throughput compound screening to identify pathways and interventions that enhance T-cell specification, alongside single-cell profiling and computational modelling. Working within a multidisciplinary team, you will generate and experimentally test mechanistic hypotheses about early human T-cell development. The discoveries may support more efficient production of PSC-derived T cells for cellular immunotherapy and provide insight into altered differentiation and lineage plasticity in blood cancers.

About you

You will have a PhD in stem cell biology, developmental biology, haematology, immunology, cancer biology, molecular/cellular biology or a related discipline. You should have substantial experience in mammalian cell culture and molecular or cellular experimentation, together with strong skills in experimental design, quantitative data interpretation and scientific communication. Experience in human pluripotent stem cells, developmental haematopoiesis, T-cell biology, flow cytometry, high-throughput screening, genome engineering, single-cell approaches, computational analysis or in vivo models would be advantageous, but we welcome applicants with complementary expertise who are keen to enter this field. You will be scientifically curious, rigorous, proactive and collaborative, with the ability to develop independent ideas while contributing positively to a multidisciplinary team.

Images created by electron microscope of blood cells from mouse embryonic stem cells in vitro (credit to T.Allen & G.Lacaud).
Paterson Building Scientific Administration

More information

Georges Lacaud

Georges is a Senior Group Leader at the CRUK Manchester Institute where he leads the Stem Cell Biology group. His research focuses on the regulation of normal haematopoiesis to better understand the development of leukaemia and other blood cancers.

Stem Cell Biology

The Stem Cell Biology group are particularly interested in understanding the mechanisms of development and maintenance of leukaemia and identifying and validating new therapeutic targets. Another focus of our work is to uncover the mechanisms of normal haematopoietic development to recapitulate this process in vitro for the generation of therapeutic immune cells. rnrnCytotoxic therapy has been the standard of care over the last 30 years for acute myeloid leukaemias (AMLs). Unfortunately, more often than not, it fails to cure patients, and the five years survival rate is only around 20%. Therefore, there is a pressing need to develop more specific and efficient therapies.rnrnTo this end, our laboratory undertakes two integrated research programmes: a) investigating mechanisms driving initiation and maintenance of leukaemia; and b) extending the understanding of normal haematopoietic system development. Our overarching goals are to improve patient outcomes by identifying and validating new therapeutic targets for leukaemia treatment and developing robust protocols for in vitro production of clinical-grade blood cells for adoptive cancer immunotherapies. rnrnWe aim to identify and validate new therapeutic targets in acute myeloid leukaemia. We are implementing advanced technologies, including single-cell multi-omics, CRISPR screening, mass spectrometry, bioinformatics, mouse models, organoid cultures and patient-derived samples analyses in these studies. We also aim to improve our understanding of blood cell development in order to better replicate this process in vitro to generate cells for adaptive cellular immunotherapies. Currently, our incomplete understanding of normal in vivo haematopoietic ontogeny limits our capacity to efficiently replicate this process in vitro. The complexity of haematopoietic development has to be comprehensively defined, and the underlying regulatory mechanisms understood to establish effective in vitro protocols that drive differentiation towards specific haematopoietic lineages.

About CRUK Manchester Institute

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. rnThe Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

Georges Lacaud
Stem Cell Biology
About CRUK Manchester Institute

How to apply

To apply for this position please complete the online application via ‘Apply Now’. Please ensure you detail the names of  three referees and ensure you submit your application before Sunday 04 October 2026.

For any informal enquiries about this post, please contact Prof Georges Lacaud:  georges.lacaud@cruk.manchester.ac.uk

Please note this vacancy will close for applications at 18:00 hours on the closing date specified.

Contact us for further information

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Images of stained cells superimposed with headshot images of Samra Turajlic and Tim Somervaille
Image of skin cancer in ageing humans

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Two Institute Scientists elected to the Academy of Medical Sciences

We celebrate the recognition Professor Samra Turajlic and Professor Tim Somervaille by a prestigious medical science institution

New publication: Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion

Research explores the role of lipid signalling in cancer behaviour

Cancer Research In the Paterson Building
Two Institute Scientists elected to the Academy of Medical Sciences
New publication: Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion